$24.74
▼ -1.2% Today
as of Sep 4, 16:56 ET
Last 30 days
Recent Press Releases & News
Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Vor Bio To Participate in Upcoming September Conferences
Wedbush Adjusts Price Target on Vor Biopharma to $27 From $18, Keeps Neutral Rating
Overview
52-week range
$6.50
$50
42% of range
Avg surprise (last 3)
-94.6%
Avg reaction (last 2)
+1.7%
50% positive
Latest IV / EM
135%
EM ±21.2% · $25 · Sep 18
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Tue Jun 30, 2026 | Jun 2026 | $-1.16 | — | — | — | — | financials |
| Wed May 13, 2026 | Mar/2026 | $-0.73 | $-0.75 | +2.7% | -180.8% | -3.4% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-121.63 | — | — | — | — | financials |
| Tue Aug 12, 2025 | Jun/2025 | $-2.18 | $-0.57 | -282.5% | — | — | earnings |
| Wed May 14, 2025 | Mar/2025 | $-0.26 | $-0.25 | -4.0% | — | +6.9% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-8.05 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.41 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.45 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.49 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $-0.45 | — | — | — | — | financials |
| Fri Mar 31, 2023 | Mar 2023 | $-0.43 | — | — | — | — | financials |
Financials
Income statement (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-48M | $-35M | — | $-28M | $-274M | $-33M | — | $-29M |
| Net income | $-63M | $-220M | — | $-813M | $-1.57B | $-32M | — | $-28M |
| EPS (diluted) | $-1.16 | $-5.11 | — | $-121.63 | $-251.24 | $-5.21 | — | $-8.05 |
Balance sheet (quarterly)
| Metric | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $108M | $170M | $396M | $160M | $191M | $50M | $82M | $53M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $475M | $501M | $458M | $172M | $205M | $65M | $97M | $67M |
| Total assets | $481M | $507M | $464M | $176M | $205M | $109M | $143M | $116M |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $681M | $657M | $628M | $2.40B | $1.71B | $43M | $46M | $43M |
| Total equity | $-200M | $-150M | $-164M | $-2.23B | $-1.51B | $66M | $-97M | $73M |